Vaccines remain one of the most effective interventions in public health, yet some of the toughest targets in modern medicine—HIV, rapidly mutating coronaviruses, and tumor antigens—exploit sugars on their surfaces to evade detection. A review by Kearns, M., et al. in Trends in Biotechnology makes the case that protein–glycan engineering is shifting vaccine design away from empirical trial-and-error and toward a rational, mechanism-guided discipline. This article summarizes the immune biology of glycans and the converging biotechnologies—CRISPR-based glycoediting, synthetic biology, glycan-modified nanoparticles, and computational modeling—that together are making next-generation glycoengineered vaccines feasible.

Why Glycans Matter in Immune Recognition

Glycans coat nearly every cell surface and act as molecular barcodes that the immune system reads continuously. Host glycan-binding proteins such as C-type lectins, siglecs, and galectins recognize pathogen-associated sugars and trigger antigen uptake, presentation, and inflammatory signaling. At the same time, glycans attached to soluble and receptor-like glycoproteins are themselves useful biomarkers for diagnosis and prognosis, as well as potential therapeutic targets. Because more than 70% of protein-based biologics—including vaccines and monoclonal antibodies—depend on glycan modifications for proper function, the structure of a sugar chain can decide whether an antigen is seen, ignored, or tolerated by the immune system. Modern Glycomics platforms and high-resolution Glycan Profiling services now make it possible to map these patterns at scale and connect specific glycoforms to immune outcomes.

Glycan Shields: How Pathogens Hide

Pathogens have learned to weaponize glycosylation. Bacteria such as Neisseria gonorrhoeae scavenge host sialic acids to block complement activation, while group A streptococci use hyaluronic acid capsules to mask immunogenic epitopes. In fungi, Candida auris can conceal β-glucans from Dectin-1, and parasites such as Trypanosoma cruzi transfer host sialic acids to their own surfaces through trans-sialidase. Viruses depend most heavily on this strategy: the envelope glycoproteins of HIV and SARS-CoV-2 are shielded by dense, complex N-glycan structures and sialic acids that physically obscure the conserved epitopes needed for neutralizing antibodies. The very modifications that stabilize a viral protein therefore also protect it from the adaptive immune system, a tension that glycoengineers now aim to exploit rather than accept.

Re-engineering the Glycan Shield on Viral Antigens

A central insight from the review is that glycans are not fixed obstacles but tunable features. On the SARS-CoV-2 spike protein, site-directed mutagenesis of N-glycosylation sequons (the N-X-S/T motif) to Q-X-S/T has been shown to expose hidden neutralizing epitopes and broaden protective responses. Conversely, adding glycans at immunodominant but variable regions can redirect immunity toward more conserved, subdominant epitopes—exactly the regions that matter for cross-variant protection. This dual strategy of deleting glycans to reveal targets and adding glycans to focus responses turns epitope accessibility into a design parameter. Such work is informed by detailed Glycomic Characterization of how glycosylation shapes antigen processing and presentation.

Fig. 1 Engineering glycan shields to reveal or focus immune responses against the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) spike (S) protein. (Kearns, et al. 2025)

CRISPR and Synthetic Biology for Programmable Glycosylation

Traditional glycan remodeling—enzymatic glycosylation or single-gene glycosyltransferase knockouts—offers limited control and scales poorly across the interconnected networks that govern glycosylation. CRISPR-based glycoengineering changes this by enabling precise, multiplexed editing of many genes at once. Genome-wide screens in cancer cells have identified specific glycan–checkpoint interactions, such as CD43 with Siglec-7 and Desmoglein-2 with Siglec-9, while FUT8-deficient CHO cells produce afucosylated antibodies with markedly stronger antibody-dependent cellular cytotoxicity. Beyond mammalian cells, engineered glycoenzymes, cell-free glycosylation platforms such as glycoSNAP, and bacterial genome-integrated systems like MAGIC are being used to make homogeneous, site-specific glycoforms for vaccines, viral immunogens, and antibodies. The ability to introduce orthogonal glycosylation pathways into CHO, yeast, plant, and E. coli hosts gives developers far finer control over composition, binding affinity, and immune modulation than conventional expression systems allow.

Nanoparticle and VLP Platforms for Glycan Antigens

Many glycans are weakly immunogenic on their own, so delivery matters. Nanoparticle (NP) platforms—virus-like particles (VLPs), liposomes, protein nanoparticles, and gold glyconanoparticles—solve this by presenting antigens in a multivalent arrangement, stabilizing them, and codelivering adjuvants. VLPs are the only NP-based vaccine technology with FDA approval to date. Qβ VLPs have been used to conjugate capsular polysaccharides from Group B Streptococcus, and hyperglycosylated hepatitis B VLPs have been engineered to display antigens that enhance uptake through lectin–glycan interactions. Gold NPs functionalized with tumor-associated carbohydrate antigens improve targeting to antigen-presenting cells, and metabolic glycan labeling of dendritic cells with azido sugars strengthens APC–T cell engagement. These strategies are supported by dedicated Glyconanoparticle Development and formulation capabilities that translate glycoengineering concepts into testable vaccine candidates.

Fig. 2 Glycan-mediated immune modulation, receptor interactions, and barriers in glycoconjugate vaccine development. (Kearns, et al. 2025)

Glycoconjugate Vaccines Move Beyond Bacteria

Classic glycoconjugate vaccines link bacterial capsular polysaccharides to carrier proteins such as CRM197, tetanus toxoid, or diphtheria toxoid, converting a T-independent response into a durable, T cell-dependent one. Licensed examples including Hib, MenACWY, and Prevnar illustrate the principle. Protein–glycan engineering is now extending this logic to new targets. In oncology, multivalent glycovaccines against CD44 glycoepitopes address tumor glycan heterogeneity, while sialoglycan-conjugated SARS-CoV-2 spike proteins tethered to Toll-like receptor-7 agonists improve stability and immunogenicity. In autoimmunity, APC-targeting glycosylated antigens can induce tolerance rather than activation, pointing toward allergy and autoimmune therapies.

Computational Glycoengineering for Rational Design

Unlike DNA or protein, glycans are not produced from a template, which makes their structures harder to predict. Machine learning trained on large glycan datasets now forecasts site occupancy, structural diversity, and binding motifs, while Markov chain models reconstruct biosynthetic pathways to pinpoint enzymatic steps worth targeting. Molecular dynamics simulations have revealed how viral glycan shields rearrange to protect epitopes, directly informing HIV and influenza vaccine design. These tools are being folded into rational pipelines that select glycan variants with better stability, reduced immunogenic tolerance, and consistent expression. Complementary profiling by O-glycan methods, Sialic Acid Analysis, and Glycan Structure Analysis anchors the models in measured data rather than assumption.

Remaining Barriers and Future Directions

Several hurdles remain before glycoengineered vaccines reach the clinic at scale. Glycosylation heterogeneity across expression systems and culture conditions undermines reproducibility, and carrier-protein reuse can trigger carrier-induced epitope suppression that blunts responses. Predicting immune reactions to engineered glycans is still imperfect, and large-scale, regulatory-compliant manufacturing of complex structures is expensive. The review argues that these problems are best addressed through interdisciplinary convergence: cell-free biosynthesis and AI-driven glycoanalytics to improve consistency, programmable glycosylation systems to control presentation, and biomaterial organoids to validate efficacy in vitro. For developers weighing where to start, a short checklist helps:

• Define the target glycoform and confirm it by Glycoprotein Enrichment and direct structural analysis before scaling.
• Choose deletion, addition, or site-specific modification of glycans based on whether the goal is exposure, focusing, or tolerance.
• Match the delivery platform—VLP, liposome, or glyconanoparticle—to the antigen's stability and multivalency needs.
• Use computational models to predict occupancy and shielding, then validate experimentally rather than relying on either alone.
• Plan manufacturing and regulatory strategy early, because glycan consistency is the main barrier to translation.

Protein–glycan engineering is reframing vaccine design as a precise, programmable discipline. By pairing classical immune mechanisms with CRISPR editing, synthetic biology, nanoparticles, and computation, researchers can now shape antigen presentation and immune activation with a control that was out of reach only a few years ago. For teams building the next generation of bacterial, viral, cancer, or autoimmune vaccines, the sugar chain is no longer a complication to work around—it is the lever.

Related Services & Products

• Glycan Release Service
• Glycan Separation and Purification Service
• Glycan Derivation Service
• N-Glycan Profiling Service
• O-Glycan Profiling Service
• Glycomic Quantitation
• Custom Glycoprotein Synthesis
• Custom Glycosylation Service
• Lectin Enrichment
• Glyco-biomarker Detection Service

Reference

1. Kearns, M., et al. (2025). Protein–glycan engineering in vaccine design: merging immune mechanisms with biotechnological innovation. Trends in Biotechnology. DOI: 10.1016/j.tibtech.2025.06.022.